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Supplementary Table 1. Summary of clinical and biological features of 30 multiple 
myeloma samples. 
 
Sample ID Age Sex Phase Ig Type Isotype Cytogenetic 
PD26400a 69 M SMM IgG Kappa HRD* 
PD26401a 74 M SMM IgG Kappa   
PD26402a 55 F SMM IgG Kappa t(11;14) 
PD26403a 57 F SMM IgG Kappa HRD 
PD26404a 64 M SMM IgG Kappa HRD 
PD26405a 64 F SMM IgA Kappa t(4;14) 
PD26406a 61 M SMM IgG Kappa t(4;14) 
PD26407a 49 M SMM IgG Kappa HRD 
PD26408a 53 M SMM IgG Kappa HRD 
PD26409a 64 F MGUS IgG Kappa HRD 
PD26410d 66 M RR IgG Lambda HRD 
PD26411c 64 M RR IgA Lambda HRD 
PD26412a 50 M RR IgG Kappa HRD 
PD26414a 54 F RR IgA Kappa t(4;14) 
PD26415c 55 M RR IgG Kappa HRD 
PD26416d 52 F RR IgG Kappa HRD 
PD26418a 71 M RR IgA Kappa t(11;14) 
PD26419a 65 F DG LC Kappa t(8q24;14) 
PD26420a 56 M RR IgM Kappa t(11;14) 
PD26422d 70 M RR IgA Kappa t(11;14) 
PD26423e 54 M RR IgG Kappa HRD 
PD26424a 63 M SMM IgG Kappa HRD 
PD26425e 63 M RR IgA Kappa t(11;14) 
PD26426e 77 M RR IgG Kappa HRD 
PD26427a 51 F DG LC Lambda t(11;14) 
PD26428a 41 M DG IgG Kappa t(11;14) 
PD26429a 64 F DG IgG Kappa HRD 
PD26432c 61 M RR IgA Lambda HRD 
PD26434c 58 M DG IgG Kappa t(11;14) 




Supplementary Figure 1. Mutational signature matrix decomposition. Schematic 
diagram explaining the mutational signature matrix decomposition according to the 
formula 𝐶 ≈ 𝑆𝐸, where 𝐶 is the catalogue matrix, with mutation types as rows and 
samples as columns, 𝑆 is the signature matrix, with mutation types as rows and 
signatures as columns, and 𝐸 is the exposure matrix, with signatures as rows and 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 2. Recurrent flat signatures in hematological cancers. The 96-
mutational profile of Signature 3, 5 and 8, all considered as “flat” signatures due to the 
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Supplementary Figure 3. Reconstruction error using MM mutational signatures. 
Reconstruction error of the 30 MM samples computed as KL divergence (KLD, top 
row), root mean squared error (RMSE, middle row) and cosine similarity (Cos Sim, 
bottom row), and using different combinations of the flat mutational signatures 
reported across different hematological malignancies (COSMIC Signatures 3, 5 and 
8): including signature 3, 5 and 8 (with Sig. 3, 5 and 8), including only signatures 3 and 
5 (without Sig. 8), including only signatures 5 and 8 (without Sig. 3), and including only 
signatures 3 and 8 (without Sig. 5). The first column (a,b,c) shows the reconstruction 
error in the three settings as boxplots, with p-values computed using a two-sided 
paired t-test; here, boxes show median, 1st and 3rd quartiles and whiskers are placed 
at the most external data point within 1.5*(75th-25th percentile). The second column 
(d,e,f) compares the reconstruction error in the setting “with Sig. 3 and 8” against 
“without Sig. 8”. The third column (g,h,i) compares “with Sig. 3, 5 and 8” against 
“without Sig. 3”; and the fourth column (j,k,l)  compares “with Sig. 3, 5 and 8” against 
“without Sig. 5”. Black lines indicate the line x = y. The data point corresponding to 






Supplementary Figure 4. Mutational signature assignment in MM. Mutations assigned 
to signatures in the 30 MM samples, using different combinations of the mutational 
signatures 3 and 8: including only signature 8 (without Sig. 3), including both 
signatures 3 and 8 (with Sig. 3 and 8). Each dot is a sample. Black lines indicate the 
line x = y. 
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Supplementary Figure 5. Indel landscape in MM and BRCA-null breast cancer. We 
annotated the indel landscape according to the recently proposed classification 1 for 
all MMs (a), for PD26419a -the case that showed a uncertain HRD- (b) and for 2 
BRCA-null breast cancers (c-d). In MMs and in PD26419a in particular we did not 
observe any enrichment for microhomology deletions as observed in the 2 
BRCA1/BRCA2 deficient breast cancers. 
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Supplementary Figure 6. The structural variant (SV) signatures for each MM case and 
for the 2 BRCA-null breast cancers. None of the MM samples had a SV signature 
profile similar to that observed among the BRCA-null breast cancers, that showed also 
a clear enrichment in term of SV prevalence. 
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Supplementary Figure 7. AID mutational signatures. The 96-mutational profile of non-
canonical AID (Signature 9, top) and canonical AID (bottom)2,3. The first is active all 
over the genome and represents one of the main mutational process in MM and M-
CLL. Conversely, the second is active only as a localized mutational process within 
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Supplementary Figure 8. CLL and MM mutation distribution on IGH. The SNV 
distribution on the IGH region of (a) M-CLLs (n=67), (b) U-CLLs (n=68) and (c) MMs 
(n=30). d) Relative and absolute mutation rate on coding gene within IGH locus. All 
cancers are subject to a different grade of c-AID activity, and, interestingly, in U-CLL 
cases this activity was mostly on the non-coding part compared to MM and M-CLL. e) 
The cancer cell fraction of all mutations within IGH/IGK/IGL loci. U-CLLs showed a 
significantly higher fraction of subclonal mutations compared to both M-CLL and MM 
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Supplementary Figure 9. Localized hypermutation on the IGH locus. In this cartoon, 
we summarized the VDJ recombination process. This recombination juxtaposes 
otherwise distant DNA segments, and once mapped to the germline reference 
genome the inter-mutational distance of c-AID localized hypermutation appears falsely 
high. The same rationale can be applied to other complex regions and events involving 
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Supplementary Figure 10. BCL6 mutational distribution. a) distribution of SNVs within 
the BCL6 gene locus for M-CLLs, U-CLLs and MMs. In contrast to the other entities, 
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Supplementary Figure 11. Relative contribution of mutational signatures in CLL. 
Hierarchical clustering based on the relative contribution of each extracted mutational 
signature among 146 CLLs. Two main group are created, one with high and one with 
low signature 9 contribution. The first is mostly composed by M-CLL conversely the 












Supplementary Figure 12. The concordance rate between the published list of CLL 
variants on the IGH/IGK/IGL loci extracted by Sidron and the one extracted by 3 
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